Minodronic acid is a third-generation
bisphosphonate drug. It is approved for use in Japan for the treatment of
osteoporosis
Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to bone fragility, and consequent increase in fracture risk. It is the most common reason for a broken bone ...
. Its
mechanism of action involves
inhibition
Inhibitor or inhibition may refer to:
In biology
* Enzyme inhibitor, a substance that binds to an enzyme and decreases the enzyme's activity
* Reuptake inhibitor, a substance that increases neurotransmission by blocking the reuptake of a neurotra ...
of
farnesyl pyrophosphate synthase
Dimethylallyltranstransferase (DMATT), also known as farnesylpyrophosphate synthase (FPPS) or as farnesyldiphosphate synthase (FDPS), is an enzyme that in humans is encoded by the FDPS gene and catalysis, catalyzes the biotransformation, trans ...
activity.
References
Bisphosphonates
Imidazopyridines
{{musculoskeletal-drug-stub